Priyanka Jain
Pulmonary Disease · Toledo, OHNPI 1124405899
Payments from drug & device makers
Across 457 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Boehringer Ingelheim$991
- Grifols USA, LLC$665
- Sanofi$595
- Inspire Medical Systems, Inc.$411
- plus $3K from 31 others
What the payments were for
- Food & beverage$8,93898%
- Education$2262%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 73 | $1,842 |
| GSK | 110 | $1,350 |
| Boehringer Ingelheim | 40 | $991 |
| Grifols USA, LLC | 31 | $665 |
| Sanofi | 35 | $595 |
| Inspire Medical Systems, Inc. | 5 | $411 |
| Insmed, Inc. | 10 | $391 |
| Regeneron Healthcare Solutions, Inc. | 21 | $386 |
| Amgen | 19 | $352 |
| Harmony Biosciences LLC | 7 | $232 |
| Philips North America LLC | 20 | $231 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $223 |
| United Therapeutics Corporation | 6 | $164 |
| Pulmonx Corporation | 6 | $151 |
| Baxter Healthcare | 6 | $140 |
| Bard Access Systems, Inc. | 1 | $140 |
| Actelion Pharmaceuticals US, Inc. | 6 | $107 |
| Viatris Specialty LLC | 5 | $95 |
| Axsome Therapeutics, Inc. | 6 | $92 |
| Genentech USA, Inc. | 4 | $83 |
| E.r. Squibb & Sons, L.L.C. | 4 | $63 |
| Mylan Specialty L.p. | 4 | $62 |
| Bayer | 3 | $54 |
| Shionogi Inc | 2 | $47 |
| Circassia Inc. | 3 | $42 |
| Verona Pharma, Inc. | 2 | $37 |
| AbbVie | 1 | $29 |
| Jazz Pharmaceuticals Inc. | 2 | $28 |
| Inogen, Inc. | 1 | $22 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Melinta Therapeutics, LLC | 1 | $18 |
| Gilead | 1 | $18 |
| Advanced Respiratory, Inc | 1 | $17 |
| Merck | 1 | $17 |
| Pfizer | 1 | $14 |
| Kaleo, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$671
- FASENRA$671
- BREZTRI$571
- AIRSUPRA$455
- Inspire$310
- BEVESPI AEROSPHERE$216
- TRELEGY ELLIPTA$121
How this compares
$9,164 in reported general payments places this provider in the 75th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 380 | $480,128 |
| OfevNintedanib Esylate | 32 | $425,535 |
| AdempasRiociguat | 12 | $154,850 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 89 | $99,524 |
| Advair HfaFluticasone Propion/Salmeterol | 132 | $64,944 |
| Spiriva RespimatTiotropium Bromide | 57 | $54,594 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 40 | $41,686 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 21 | $20,932 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $15,322 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 345 | $11,837 |
| DuleraMometasone/Formoterol | 14 | $9,660 |
| Roflumilast | 58 | $9,542 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $9,454 |
| Wixela InhubFluticasone Propion/Salmeterol | 17 | $5,711 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 40 | $5,398 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $1,350 | $537,136443 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $991 | $501,061110 claims |
| BayerAdempas | $54 | $154,85012 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,842 | $108,977112 claims |
| MerckDulera | $17 | $9,66014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Toledo
- James TitaToledo$310K
- Salil AvasthiToledo$220K
- Bruce CorserCincinnati$8.2M
- Edward CordascoColumbus$8M
- Kristin HighlandCleveland$3.2M
- Brian ZenoColumbus$2.9M
- Jean ElwingCincinnati$2.4M
- Roy St JohnColumbus$1.9M
- Nishant GuptaCincinnati$1.5M
- Robert BaughmanCincinnati$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.